GoodRx Holdings, Inc. (GDRX - Free Report) reported $196.64 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 6.8%. EPS of $0.08 for the same period compares to $0.07 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $195.59 million, representing a surprise of +0.54%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.08.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how GoodRx Holdings, Inc. performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Monthly Active Consumers: 6 versus the four-analyst average estimate of 6.
- Subscribers: 884 versus 987 estimated by three analysts on average.
- Revenue- Prescription transactions: $143.86 million compared to the $138.50 million average estimate based on six analysts. The reported number represents a change of +11.2% year over year.
- Revenue- Other: $5.23 million compared to the $5.15 million average estimate based on six analysts. The reported number represents a change of +0.5% year over year.
- Revenue- Subscription: $23.15 million versus $22.99 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -5.9% change.
- Revenue- Pharma Manufacturer Solutions: $24.40 million versus the five-analyst average estimate of $27.46 million. The reported number represents a year-over-year change of -2%.
View all Key Company Metrics for GoodRx Holdings, Inc. here>>>Shares of GoodRx Holdings, Inc. have returned +27.1% over the past month versus the Zacks S&P 500 composite's +5.2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
GoodRx Holdings, Inc. (GDRX - Free Report) reported $196.64 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 6.8%. EPS of $0.08 for the same period compares to $0.07 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $195.59 million, representing a surprise of +0.54%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.08.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how GoodRx Holdings, Inc. performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Monthly Active Consumers: 6 versus the four-analyst average estimate of 6.
- Subscribers: 884 versus 987 estimated by three analysts on average.
- Revenue- Prescription transactions: $143.86 million compared to the $138.50 million average estimate based on six analysts. The reported number represents a change of +11.2% year over year.
- Revenue- Other: $5.23 million compared to the $5.15 million average estimate based on six analysts. The reported number represents a change of +0.5% year over year.
- Revenue- Subscription: $23.15 million versus $22.99 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -5.9% change.
- Revenue- Pharma Manufacturer Solutions: $24.40 million versus the five-analyst average estimate of $27.46 million. The reported number represents a year-over-year change of -2%.
View all Key Company Metrics for GoodRx Holdings, Inc. here>>>Shares of GoodRx Holdings, Inc. have returned +27.1% over the past month versus the Zacks S&P 500 composite's +5.2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on GDRX - FREE